分泌抗 EpCAM 双特异性 T 细胞衔接器的 CAR-T 细胞克服靶向上皮来源癌时的肿瘤异质性

CAR T cells secreting anti-EpCAM bispecific T cell engagers overcome tumor heterogeneity in targeting epithelial-originated carcinomas.

CD4(+) 抗 TGF-β CAR-T 细胞与 CD8(+) 常规 CAR-T 细胞表现出协同抗肿瘤效应

CD4(+) anti-TGF-β CAR T cells and CD8(+) conventional CAR T cells exhibit synergistic antitumor effects.

靶向 Glypican 3 的 CAR-T 细胞分泌靶向 TROP2 的双特异性 T 细胞衔接器对肺鳞状细胞癌表现出强效疗效

Glypican 3-targeted chimeric antigen receptor T cells secreting TROP2-directed bispecific T cell engagers exhibit potent efficacy against lung squamou

本研究表明，GPC3 CAR-T。

全球现有 CAR-T 细胞试验的系统综述

Systematic Review of Available CAR-T Cell Trials around the World.

靶向 GPC3 的 CAR-T 细胞理性设计：毒性与治疗疗效解耦

Rational design of chimeric antigen receptor T cells against glypican 3 decouples toxicity from therapeutic efficacy.

通过将降低亲和力的 CAR 与此外源性控制机制相结合，我们提供了证据表明我们可以调节和控制 CAR 介导的毒性。

DAP10 整合入 CAR-T 细胞通过利用内源性 NKG2D 增强对异质性肿瘤的杀伤

DAP10 integration in CAR-T cells enhances the killing of heterogeneous tumors by harnessing endogenous NKG2D.

Glypican-3 (GPC3) 与 Merkel 细胞癌中 MCPyV 阴性状态及不良预后相关

Glypican-3 (GPC3) is associated with MCPyV-negative status and impaired outcome in Merkel cell carcinoma.

GPC3 在 MCC 肿瘤中频繁表达，尤其是在 MCPyV 阴性病例中，并与死亡风险增加相关。表面 GPC3 的高表达使其成为假定的药物靶点。